Hernandez R, Torres M D, Campillo J E
Department of Physiology, Faculty of Medicine, University of Extremadura, Badajoz, Spain.
Diabete Metab. 1991 Mar-Apr;17(2):281-5.
The effect of subcutaneous cyclosporin administration (20 mg/kg) on the development of complete Freund's adjuvant (CFA)-streptozotocin-induced diabetes and on the induction of the so called cyclosporine diabetes like syndrome, were examined in Wistar rats. During and 5 weeks after the cyclosporin A treatment (21 days) the rats remained normoglycaemic. Three injections of 30 mg/kg streptozotocin given at weekly intervals, 24 hr after the administration of CFA, produced a persistent hyperglycaemia, an impairment of glucose tolerance and a drastic reduction in the pancreatic insulin content. The development of the diabetic state was prevented by cyclosporin treatment. The present results suggest that the cyclosporin diabetes like syndrome could not appear when cyclosporin was administered subcutaneously at the recommended doses for immunosuppression and that at such therapeutic doses, cyclosporin inhibits the development of CFA-Streptozotocin-induced diabetes in the Wistar rat.
在Wistar大鼠中,研究了皮下注射环孢素(20毫克/千克)对完全弗氏佐剂(CFA)-链脲佐菌素诱导的糖尿病发展以及所谓环孢素糖尿病样综合征诱导的影响。在环孢素A治疗期间(21天)及治疗后5周,大鼠血糖保持正常。在给予CFA 24小时后,每周间隔注射3次30毫克/千克链脲佐菌素,导致持续高血糖、葡萄糖耐量受损以及胰腺胰岛素含量急剧降低。环孢素治疗可预防糖尿病状态的发展。目前的结果表明,当以推荐的免疫抑制剂量皮下注射环孢素时,环孢素糖尿病样综合征不会出现,并且在这种治疗剂量下,环孢素可抑制Wistar大鼠中CFA-链脲佐菌素诱导的糖尿病的发展。